Abstract
This market insight report on Angiogenesis Modulators studies the impact of
Inhibitors and Stimulators on various diseases. The study focuses on major
angiogenesis inhibitors and their role in diseases such as cancer,
dermatology, ophthalmology, rheumatology and other angiogenesis based diseases
including endometriosis and inflammatory diseases. The emphasis is also given
on major angiogenesis stimulators and their role in diseases such as
cardiovascular disorders including ischemia, congestive heart failure,
coronary artery disease, myocardial infarction and peripheral vascular disease
and chronic wound care.
The study provides global market analysis for angiogenesis therapeutic
products by the above angiogenesis modulators and also by the disease areas
such as cancer, cardiovascular disorders and other angiogenesis based
diseases. The study includes estimates and projections for the total global
angiogenesis therapeutic products market. Projections and estimates are also
illustrated by geographic regions encompassing United States, Europe,
Asia-Pacific and Rest of World. Business profiles of 34 major companies are
discussed in the report.
The report serves as a guide to global angiogenesis industry covering 325
companies engaged in angiogenesis research, testing and supply of products and
services. Major Contract Research Organizations and Universities serving
angiogenesis industry are also covered in the Corporate Directory section of
this report. Information related product developments, partnerships,
collaborations, and mergers and acquisitions are also covered in the report
featuring 95 graphically represented exclusive exhibits.
View Cart
